Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals executives highlighted its oncology growth strategy and early commercial progress for recently launched therapies at the Morgan Stanley Global Healthcare Conference. Management also outlined business-development priorities, signaling continued focus on expanding its oncology portfolio, though no financial targets or material transaction details were disclosed.